Click here to join

Press releases.

Press releases 2017

Press releases 2017
December 13th 2017

Operational Update

November 29th 2017

Prima BioMed Becomes Immutep

November 23rd 2017

Prima Secures European Patent Grant for Lead Product IMP321 in Cancer

November 21st 2017

Prima BioMed Changes its Name to Immutep Ltd

November 21st 2017

FAQ - Change of company name from 'Prima BioMed Limited' to 'Immutep Limited'

November 18th 2017

Chairman’s Address 2017 Annual General Meeting

November 18th 2017

Results of Annual General Meeting

November 18th 2017

Annual General Meeting CEO Presentation

November 16th 2017

Eftilagimod Alpha (LAG-3Ig or IMP321) Pre-IND Meeting with the FDA

November 10th 2017

New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting

November 2nd 2017

Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017

October 21st 2017

Dr. Frédéric Triebel presenting at the World Immunotherapy Congress 2017

October 18th 2017

Notice of Annual General Meeting/Proxy Form

October 18th 2017

IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting

September 9th 2017

Prima Secures Japanese Patent Grant for IMP731 Antibody

September 6th 2017

Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease

August 31st 2017

Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research Project

August 22nd 2017

Prima BioMed Appoints Non-Executive Director to the Board

August 22nd 2017

Appendix 3X

August 8th 2017

Appendix 3B

August 8th 2017

Appendix 3Y

August 7th 2017

Prima BioMed Receives A$1.3 Million Tax Refund from French Government

July 19th 2017

Financial Update 2H17

July 18th 2017

Prima BioMed Announces Second Milestone Payment for IMP701 Program

July 11th 2017

Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial

July 7th 2017

Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)

July 7th 2017

Cleansing Notice

July 5th 2017

Appendix 3B – US$5m Capital Raising

July 4th 2017

Final Prospectus Supplement

July 1st 2017

Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary Shares

June 27th 2017

Operational Update

June 6th 2017

LAG-3Ig (IMP321) demonstrates positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial

June 6th 2017

ASCO Poster 2017

June 2nd 2017

Prima BioMed Announces Formation of Clinical Advisory Board

May 19th 2017

Data from Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference

April 20th 2017

Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial

April 13th 2017

Prima BioMed receives A$492,144 Tax Refund from Australian Government

March 16th 2017

Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston

March 2nd 2017

USA Patent Grants for IMP321 in Cancer

February 25th 2017

First Half 2017 Operational Update

February 14th 2017

Prima BioMed Receives ~A$860,000 Tax Credit Payment from French Government

January 24th 2017

Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference

January 21st 2017

Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer

January 19th 2017

Prima BioMed to Maintain NASDAQ Listing

January 13th 2017

Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial

January 6th 2017

Prima BioMed enters new Material Transfer Agreement with Cytlimic

January 3rd 2017

Prima announces new Product Candidate IMP761 – a LAG-3 Agonist Antibody